2. Search Result
Search Result
Results for "

lipid levels

" in MedChemExpress (MCE) Product Catalog:

261

Inhibitors & Agonists

2

Screening Libraries

10

Biochemical Assay Reagents

11

Peptides

1

MCE Kits

3

Inhibitory Antibodies

85

Natural
Products

11

Isotope-Labeled Compounds

3

Click Chemistry

6

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-17408
    Mevastatin
    5+ Cited Publications

    Compactin; ML236B

    		 HMG-CoA Reductase (HMGCR) Bacterial Autophagy Apoptosis Antibiotic Infection Cardiovascular Disease Neurological Disease Metabolic Disease Cancer
    Mevastatin (Compactin) is a first HMG-CoA reductase inhibitor that belongs to the statins class. Mevastatin is a lipid-lowering agent, and induces apoptosis, arrests cancer cells in G0/G1 phase. Mevastatin also increases endothelial nitric oxide synthase (eNOS) mRNA and protein levels. Mevastatin has antitumor activity and has the potential for cardiovascular diseases treatment .
    Mevastatin
  • HY-N2118
    Bilobetin
    2 Publications Verification

    		 PPAR PKA Akt p38 MAPK ERK Metabolic Disease
    Bilobetin, an active component of Ginkgo biloba, can reduce blood lipids and improve the effects of insulin. Bilobetin ameliorated insulin resistance, increased the hepatic uptake and oxidation of lipids, reduced very-low-density lipoprotein triglyceride secretion and blood triglyceride levels, enhanced the expression and activity of enzymes involved in β-oxidation and attenuated the accumulation of triglycerides and their metabolites in tissues. Bilobetin also increased the phosphorylation, nuclear translocation and activity of PPARα accompanied by elevated cAMP level and PKA activity .
    Bilobetin
  • HY-129457
    FINO2
    10+ Cited Publications

    		 Ferroptosis Cancer
    FINO2 is a potent ferroptosis inducer. FINO2 inhibits GPX4 activity. FINO2 is a stable oxidant that oxidizes ferrous iron and stable at varying pH levels. FINO2 causes widespread lipid peroxidation .
    FINO2
  • HY-113168
    Butyrylcarnitine
    1 Publications Verification

    		 Endogenous Metabolite Cardiovascular Disease Metabolic Disease Cancer
    Butyrylcarnitine is an endogenous metabolite found in plasma. Elevated levels of Butyrylcarnitine are closely associated with abnormalities in lipid and energy metabolism. Butyrylcarnitine can serve as a diagnostic and prognostic indicator for certain diseases, such as heart failure and head and neck cancer .
    Butyrylcarnitine
  • HY-153910
    AGPS-IN-1

    		Others Cancer
    AGPS-IN-1 (Compound 2i) is an effective AGPS binder. AGPS-IN-1 reduces ether lipids levels and cell migration rate. AGPS-IN-1 inhibits epithelial-mesenchymal transition (EMT) in prostate PC-3 and breast MDA-MB-231 cancer cells .
    AGPS-IN-1
  • HY-109523
    Cerivastatin sodium
    2 Publications Verification

    		 HMG-CoA Reductase (HMGCR) Ferroptosis Cardiovascular Disease Cancer
    Cerivastatin sodium is a synthetic lipid-lowering agent and a highly potent, well-tolerated and orally active HMG-CoA reductase inhibitor, with a Ki of 1.3 nM/L. Cerivastatin sodium reduces low-density lipoprotein cholesterol levels. Cerivastatin sodium also inhibits proliferation and invasiveness of MDA-MB-231 cells, mainly by RhoA inhibition, and has anti-cancer effect .
    Cerivastatin sodium
  • HY-N2468
    Xylobiose

    1,4-β-D-Xylobiose; 1,4-D-Xylobiose

    		 TNF Receptor Claudin HSP Metabolic Disease Inflammation/Immunology
    Xylobiose (1,4-β-D-Xylobiose; 1,4-D-Xylobiose) is an orally active Claudin 2/CLDN2 inhibitor and HSP27 inducer. Xylobiose works by regulating intestinal barrier function and glucose and lipid metabolism-related signaling pathways. Xylobiose inhibits CLDN2 expression to reduce intestinal permeability, induces HSP27 to enhance cell protection, and regulates the miR-122a/miR-33a axis to inhibit liver lipid synthesis and improve insulin resistance. Xylobiose can strengthen intestinal barrier integrity, reduce blood sugar and blood lipid levels, and reduce oxidative stress and inflammatory response. Xylobiose can be used in the study of type 2 diabetes and metabolic syndrome .
    Xylobiose
  • HY-110150
    UNC3230
    5+ Cited Publications

    		 PI4P5K Neurological Disease Inflammation/Immunology Cancer
    UNC3230 is a potent, selective and ATP-competitive PIP5K1C inhibitor with an IC50 of ~41 nM. UNC3230 also inhibits PIP4K2C and does not inhibit any of the other lipid kinases that regulate phosphoinositide levels. UNC3230 has antinociceptive and anticancer effects .
    UNC3230
  • HY-100313A
    YM-53601
    5 Publications Verification

    		 Farnesyl Transferase HCV Infection Metabolic Disease
    YM-53601, a squalene synthase inhibitor, reduces plasma cholesterol and triglyceride levels in vivo . YM-53601 inhibits squalene synthase derived from human hepatoma cells with an IC50 of 79 nM. Lipid-lowering agent . YM-53601 is also an inhibitor of farnesyl-diphosphate farnesyltransferase 1 (FDFT1) enzyme activity and abrogates HCV propagation .
    YM-53601
  • HY-N1967
    Dihydrocurcumin

    		PNPLA3 Metabolic Disease
    Dihydrocurcumin, a major metabolites of curcumin, reduces lipid accumulation and oxidative stress. Dihydrocurcumin regulates mRNA and protein expression levels of SREBP-1C, PNPLA3 and PPARα, increases protein expression levels of pAKT and PI3K, and reduced the levels of cellular NO and ROS via Nrf2 signaling pathways .
    Dihydrocurcumin
  • HY-N3029
    Noreugenin
    2 Publications Verification

    		 Interleukin Related Apoptosis Glutathione Peroxidase SOD Glutathione S-transferase Necroptosis Inflammation/Immunology
    Noreugenin is a phenolic compound found in Calea uniflora Less. Noreugenin inhibits myeloperoxidase activity and reduces levels of proinflammatory cytokines IL-1β and IL-17A levels in LPS (HY-D1056)-induced murine pleurisy model. Noreugenin reduces apoptosis and necrosis. Noreugenin reduces lipid peroxidation, and antioxidant enzyme (CAT, SOD, GST) activity. Noreugenin exhibits anti-inflammatory and antioxidant effects. Noreugenin can be used for the research of inflammatory conditions, such as pleurisy .
    Noreugenin
  • HY-P99505
    Ziltivekimab

    COR-001; MEDI-5117; MEDI-5117; NN-6018; WBP-216

    		 Interleukin Related LDLR Inflammation/Immunology Endocrinology
    Ziltivekimab (COR-001) is a fully human monoclonal antibody and also an IL-6 inhibitor. Ziltivekimab significantly reduces inflammatory biomarkers and Lipoprotein (a) in chronic kidney disease patients with systemic inflammation. Ziltivekimab does not increase pro-atherosclerotic lipid levels. Ziltivekimab is used in studies related to atherosclerotic thrombotic diseases and chronic kidney disease .
    Ziltivekimab
  • HY-W015780
    1,4-Dimethoxybenzene

    		Environmental Pollutants Endogenous Metabolite Metabolic Disease
    1,4-Dimethoxybenzene is an endogenous metabolite. 1,4-Dimethoxybenzene has an anti-anxiety effect, increasing atherogenic index (AI) levels in rabbits and inducing sedentary behavior. Sedentary behavior may increase blood cholesterol levels and disrupt blood lipids . 1,4-Dimethoxybenzene considers to be not clastogenic in the in vivo micronucleus test .
    1,4-Dimethoxybenzene
  • HY-161929
    GPX4 activator 2

    		Glutathione Peroxidase Ferroptosis Cardiovascular Disease
    GPX4 activator 2 is a GPX4 activator with a Ka value of 0.426 μM for human GPX4. GPX4 activator 2 reduces lipid hydroperoxide levels, prevents lipid peroxide accumulation, and inhibits ferroptosis. GPX4 activator 2 rescues cell death induced by Erastin (HY-15763). GPX4 activator 2 exerts cardioprotective effects in a mouse model of doxorubicin (HY-15142A)-induced myocardial injury .
    GPX4 activator 2
  • HY-141452
    Propanedial (13.88 mM in water)

    Malondialdehyde

    		 Endogenous Metabolite Neurological Disease
    Propanedial (Malondialdehyde) (13.88 mM in water) is one of the final products of lipid peroxidation. Propanedial causes protein inactivation, DNA damage and cross-linking by forming stable covalent adducts with biological macromolecules, which is the main mechanism for its cytotoxicity and genotoxicity. Propanedial production increases with the elevation of free radicals. Propanedial is a key biomarker for evaluating the level of cellular oxidative stress [1][2][3].
    Propanedial (13.88 mM in water)
  • HY-N3031
    Grosvenorine

    		Bacterial Apoptosis Bcl-2 Family MDM-2/p53 Glutathione Peroxidase SOD TNF Receptor Interleukin Related Infection Inflammation/Immunology
    Grosvenorine is an orally active flavonoid glycoside found in S. grosvenorii. Grosvenorine exhibits antibacterial, antioxidant and antiinflammation activities. Grosvenorine can induce apoptosis and increases anti-apoptotic Bcl-2 protein expression and reduces pro-apoptotic P53 protein expression in gastric tissues. Grosvenorine enhances mucin/glycoprotein secretion, regulates gastric pH, and reduces gastric lesion incidence.Grosvenorine increases glutathione peroxidase, catalase, and SOD levels, reduces lipid peroxidation (MDA), and lowers TNF-α and IL-6 levels. Grosvenorine can be used for the researches of bacterial infection and Gastric ulcer .
    Grosvenorine
  • HY-B0417A
    Lincomycin hydrochloride
    5 Publications Verification

    U10149A

    		 DNA/RNA Synthesis Antibiotic Bacterial Infection Metabolic Disease
    Lincomycin hydrochloride (U10149A) is an orally active lincosamide antibiotic. Lincomycin hydrochloride binds to the ribosomes of Gram-positive bacteria to inhibit protein synthesis. Lincomycin hydrochloride can inhibit chloroplast translation, disrupt chloroplast integrity, and activate chloroplast-to-nucleus retrograde signaling in Arabidopsis thaliana seedlings. Lincomycin hydrochloride induces alterations in lipid profiles and liver injury, disrupts blood glucose and insulin levels, and increases growth rate in mice .
    Lincomycin hydrochloride
  • HY-162562
    E28362

    		PCSK9 Metabolic Disease Inflammation/Immunology
    E28362 is an orally active lipid-lowering agent and a selective PCSK9 antagonist. E28362 blocks the interaction between PCSK9 and LDLR, and induces PCSK9 degradation via the ubiquitin-proteasome pathway. E28362 significantly increases the levels of cell surface and total LDLR proteins, enhances low-density lipoprotein uptake, thereby effectively reducing plasma lipids, hepatic cholesterol and triglyceride levels. E28362 shows no obvious cytotoxicity at high concentrations, and significantly attenuates atherosclerotic lesions in animal models. E28362 is an important molecule in research of hyperlipidemia and atherosclerosis .
    E28362
  • HY-N0309
    Soyasaponin Ba
    1 Publications Verification

    		 Aldose Reductase Akt GSK-3 β-catenin Reactive Oxygen Species (ROS) Mitochondrial Metabolism Apoptosis c-Myc Metabolic Disease
    Soyasaponin Ba is a soyasaponin that can be isolated from Phaseolus vulgaris, acts as an aldose reductase inhibitor (ARI). Soyasaponin Ba activates Akt/GSK3β/β-catenin signaling pathway, reduces lipid accumulation, lowers ROS generation, improves mitochondrial membrane potential, ATP levels, and morphology, and inhibits apoptosis. Soyasaponin Ba can be used for the research of lipid accumulation and secondary diabetic complications .
    Soyasaponin Ba
  • HY-B1608
    Chromium chloride

    		Cardiovascular Disease Metabolic Disease
    Chromium chloride is a trivalent chromium compound and an essential trace mineral. Chromium chloride enhances insulin-stimulated GLUT4 translocation and glucose uptake in skeletal muscle. Chromium chloride regulates glucose and lipid metabolism, inhibits TNF-α secretion and oxidative stress in monocytes treated with high glucose or H2O2, and reverses hydrogen peroxide-induced cell growth inhibition. Chromium chloride reduces coronary and aortic lipid deposition and serum cholesterol levels in hypercholesterolemic rabbits. Chromium chloride can be used in research related to diabetes and cardiac atherosclerosis .
    Chromium chloride
  • HY-135115
    Oleuropein Aglycone

    3,4-DHPEA-EA

    		 α-synuclein HDAC Adrenergic Receptor Inflammation/Immunology
    Oleuropein Aglycone (3,4-DHPEA-EA) is a polyphenol and the aglycone form of oleuropein (HY-N0292), formed by enzymatic, acidic or acetylated hydrolysis of oleuropein. Dietary intake of oleuropein Aglycone (50 mg/kg diet) increases the number of neuronal autophagic vesicles, reverses cognitive deficits in the TgCRND8 transgenic mouse model of Alzheimer's disease, and reduces the levels of histone deacetylase 2 (HDAC2) in the cortex and hippocampus. Oleuropein Aglycone increases urinary norepinephrine, interscapular brown adipose tissue epinephrine, and UCP1 protein levels, and reduced plasma leptin levels and total abdominal adipose tissue weight in a rat model of high-fat diet-induced obesity. Oleuropein Aglycone also reduced lung neutrophil infiltration, lipid peroxidation, and IL-1β levels in a mouse model of carrageenan-induced pleurisy.
    Oleuropein Aglycone
  • HY-W984782
    Flindersine

    		GLUT Bacterial Fungal AMPK PPAR Reactive Oxygen Species (ROS) Apoptosis SOD Infection Metabolic Disease Cancer
    Flindersine is an alkaloid with multiple activities including antibacterial, antifungal, antitumor, and antidiabetic properties. Flindersine increases the activity of antioxidant enzymes, restores the levels of renal biomarkers, and reduces blood glucose, blood lipid, and insulin levels in diabetic rats. Flindersine inhibits the growth of Gram-positive bacteria, Gram-negative bacteria, drug-resistant bacteria, as well as dermatophytes, filamentous fungi, and yeasts. Flindersine reduces the viability of cancer cells and induces apoptosis. Flindersine can be used in research related to breast cancer, type 2 diabetes, bacterial infections, and fungal infections .
    Flindersine
  • HY-162353
    AZ'9567

    		Cancer
    AZ'9567 is an orally active MAT2a inhibitor with a pIC50 of 9.1. AZ'9567 binds to MAT2a allosterically, reduces the synthesis of SAM, decreases SDMA levels, and exerts antiproliferative effects on MTAP-knockout cells. AZ'9567 depletes SAM, causes methionine accumulation in plasma and tissues, triggers adaptive disorders in one-carbon metabolism, transsulfuration metabolism and lipid metabolism, and induces oxidative stress, hepatic steatosis and lipid homeostasis imbalance. AZ'9567 can be used in studies related to MTAP-deficient/deleted cancers .
    AZ'9567
  • HY-160552
    244cis

    		Liposome Others
    244cis, a piperazine-containing ionizable cationic lipid, has been used to generate lipid nanoparticles (LNPs). LNPs containing 244cis and coated with mRNA reporter gene were specifically accumulated in mouse lungs compared with LNPs containing SM-102. Induces a decrease in serum chemokine (C-C motif) ligand 2 (CCL2) levels .
    244cis
  • HY-101529
    Imanixil

    HOE-402free base

    		 LDLR Cardiovascular Disease
    Imanixil (HOE-402 free base) is an orally active LDL receptor (LDLR) inducer. Imanixil can reduce cholesterol levels by inhibiting VLDL-lipid production. Imanixil can delay atherosclerosis profession. Imanixil can be used for the research of cardiovascular disease, such as atherosclerosis .
    Imanixil
  • HY-N14035
    Garcinia cambogia extract

    		FABP PPAR Metabolic Disease
    Garcinia cambogia extract is an orally active anti-obesity agent . Garcinia cambogia extract upregulates the gene expression of aP2, SREBP1c, PPARγ2 and C/EBPα. Garcinia cambogia extract reduces the rate of body weight gain, visceral fat accumulation, lipid levels in blood and liver, as well as plasma insulin and leptin levels . Garcinia cambogia extract ameliorates high-fat diet-induced obesity .
    Garcinia cambogia extract
  • HY-149120
    ASM-IN-1

    		Phospholipase Cardiovascular Disease Inflammation/Immunology
    ASM-IN-1 is a potent and orally active acid sphingomyelinase (ASM) inhibitor with an IC50 value of 1.5 µM. ASM-IN-1 reduces lipid plaques in the aortic arch and aorta and reduces plasma ceramide concentration and Ox-LDL levels. ASM-IN-1 shows antiatherosclerotic and anti-inflammatory activity .
    ASM-IN-1
  • HY-117912
    TRC210258

    		Endogenous Metabolite Cardiovascular Disease
    TRC210258 is a TGR5 agonist with activity to improve diabetes-associated hyperglycemia and dyslipidemia. TRC210258 promotes energy expenditure by enhancing the release of glucagon-like peptide-1. TRC210258 is able to improve glucose metabolic control in high-fat diet-induced obese mice. TRC210258 also showed improvement in lipid parameters in high-fat-fed hamsters, including reductions in plasma triglyceride and low-density lipoprotein cholesterol levels. TRC210258 improved emerging lipid-related cardiovascular risk parameters including remnant cholesterol and triglyceride clearance .
    TRC210258
  • HY-176557
    NCI677397

    		Deubiquitinase Ferroptosis Reactive Oxygen Species (ROS) Glutathione Peroxidase Autophagy Cancer
    NCI677397 is a USP24 inhibitor. NCI677397 increases lipid ROS, activates cholesterol and fatty acid biosynthesis, degrades ABC transporters, GPX4 and DHFR through the autophagy pathway, decreases the level of P-gp and ultimately leads to ferroptosis in drug-resistant cancer cells. NCI677397 can be used for the study of lung caner and brain cancer .
    NCI677397
  • HY-125539
    Roridin E

    		Antibiotic Phosphatase Fungal Infection
    Roridin E is a glucose-6-phosphatase (G6Pase) inhibitor and antibiotic, and is a metabolic byproduct of Roridin A (HY-N9599). Roridin E induces significant oxidative stress, characterized by depletion of glutathione in vivo, induction of hepatic lipid peroxidation, and inhibition of renal superoxide dismutase activity. Roridin E reduces blood glucose levels in rats, but exhibits acute toxicity (which is enhanced when co-administered with linoleic acid (HY-N0729)) and causes hepatotoxicity in male albino mice. Roridin E induces a decrease in total blood protein and increases in the levels of total lipids, γ-glutamyltransferase, alkaline phosphatase, and 5'-nucleotidase. Roridin E can be isolated from molds, and possesses cytostatic and antifungal activities similar to those of Verrucarin A (HY-107426) and Roridin A. Roridin E exhibits in vivo activity in rodents and is commonly used in hepatotoxicity-related studies .
    Roridin E
  • HY-163654
    Ferroptosis-IN-8

    		Ferroptosis Cancer
    Ferroptosis-IN-8 is a potent ferroptosis inhibitor with an EC50 of 40.49 nM. Ferroptosis-IN-8 effectively reduces lipid ROS levels in cells. Ferroptosis-IN-8 act as an antioxidant by capturing lipid radicals, leading to a reduction in the accumulation of harmful lipid peroxides and, ultimately, inhibiting ferroptosis .
    Ferroptosis-IN-8
  • HY-106281
    Bemfivastatin

    PPD 10558

    		 HMG-CoA Reductase (HMGCR) Metabolic Disease
    Bemfivastatin (PPD 10558) is an orally active HMG-CoA Reductase (HMGCR) inhibitor. Bemfivastatin enhances the activity of liver extraction and reduces blood lipid levels. Bemfivastatin can be used for research of metabolic disease, such as hypercholesterolemia .
    Bemfivastatin
  • HY-E70523
    Pentanoyl coenzyme A

    Valeryl-CoA; Valeryl-coenzyme A; Pentanoyl coenzyme A free acid

    		 Endogenous Metabolite Metabolic Disease
    Pentanoyl coenzyme A (Valeryl-CoA) is a short-chain fatty acyl-CoA that functions as an intermediate in mitochondrial β-oxidation and related metabolic pathways. Pentanoyl coenzyme A results from the formal condensation of the thiol group of coenzyme A with the carboxy group of pentanoic acid. Pentanoyl coenzyme A's levels can reflect changes in lipid metabolism under different physiological and pathological conditions. Pentanoyl coenzyme A can be used for research on lipid metabolism .
    Pentanoyl coenzyme A
  • HY-100469
    LXRβ agonist-2

    		LXR Inflammation/Immunology
    LXRβ agonist-2 is an orally active and selective LXRβ agonist. LXRβ agonist-2 increases high-density lipoprotein cholesterol levels without elevating plasma triglyceride levels. LXRβ agonist-2 decreases lipid accumulation area in the aortic arch. LXRβ agonist-2 can be used for the research of atherosclerosis .
    LXRβ agonist-2
  • HY-168533
    ZG-2305

    		HIF/HIF Prolyl-Hydroxylase Metabolic Disease
    ZG-2305 is a potent, orally active and selective factor inhibiting hypoxia-inducible factor (FIH) inhibitor with Ki values of 79.6, 2786 nM for FIH, PHD2, respectively. ZG-2305 increases the expression of EGLN3 gene. ZG-2305 decreases the cellular triglycerides levels and reduces lipid accumulation. ZG-2305 has the potential for the research of obesity and fatty liver disease .
    ZG-2305
  • HY-E70599
    Human CES2 Enzyme

    		Carboxylesterase (CES) Metabolic Disease
    Human CES2 Enzyme is a carboxylesterase involved in drug metabolism and lipid homeostasis. Human CES2 Enzyme hydrolyzes triglycerides, cholesteryl esters and retinyl esters to regulate lipid metabolism and energy homeostasis. Human CES2 Enzyme improves glucose tolerance and insulin sensitivity, reduces hepatic lipid accumulation, alleviates white adipose tissue steatitis, decreases plasma cholesterol levels, and reduces body weight and white adipose tissue weight. Human CES2 Enzyme can be used in the research of metabolic syndrome .
    Human CES2 Enzyme
  • HY-129458
    Cerivastatin

    		HMG-CoA Reductase (HMGCR) Ferroptosis Cardiovascular Disease Cancer
    Cerivastatin is a synthetic lipid-lowering agent and a highly potent, well-tolerated and orally active HMG-CoA reductase inhibitor, with a Ki of 1.3 nM/L. Cerivastatin reduces low-density lipoprotein cholesterol levels. Cerivastatin also inhibits proliferation and invasiveness of MDA-MB-231 cells, mainly by RhoA inhibition, and has anti-cancer effect .
    Cerivastatin
  • HY-142125
    Broussochalcone A

    		Xanthine Oxidase Reactive Oxygen Species (ROS) Apoptosis Inflammation/Immunology Cancer
    Broussochalcone A is an antioxidant and an inhibitor of Xanthine Oxidase (IC50=2.21 μM), with free radical scavenging activity. Broussochalcone A inhibits iron-induced lipid peroxidation and nitric oxide synthesis in lipopolysaccharide (LPS) -activated macrophages. Broussochalcone A also induces Apoptosis of human renal carcinoma cells by increasing ROS levels and activating FOXO3 signaling pathways .
    Broussochalcone A
  • HY-159709
    VL-422

    		Liposome Metabolic Disease
    VL-422 is an ionizable cationic lipid. VL-422 delivers CRISPR complementary single-guide RNA (sgRNA) and Cas9 mRNA to enable in vitro and in vivo gene editing. LNPs containing VL-422 loaded with Cas9 mRNA and sgRNA targeting the ANGPTL3 gene induce the deletion of premature stop codons within the ANGPTL3 gene in the liver of cynomolgus monkeys. Loss-of-function of ANGPTL3 leads to decreased levels of LDL, HDL and cholesterol in plasma. The VL-422 delivery system can be used for the research of gene editing strategies targeting lipid metabolism diseases .
    VL-422
  • HY-156277
    SP4f

    		PPAR Metabolic Disease
    SP4f is an activator ofPPAR-γ, with the EC50 of 826 nM in HK-2 cells. SP4f reduces the blood glucose levels and lipid peroxidation, and increases glutathione levels and catalase activityin the Swiss albino mice .
    SP4f
  • HY-N16658
    Asperilin

    NSC 85238

    		 Glutathione Peroxidase Inflammation/Immunology
    Asperilin (NSC 85238) is an orally active sesquiterpene lactone. Asperilin is an effective hydroxyl radical scavenger. Asperilin significantly enhance the lipid peroxidation levels of liver microsomes in various systems. Asperilin leads to a significant decrease in liver glutathione (GSH) levels and an increase in glutathione peroxidase (GPx) activity. Asperilin can be used for research on inflammatory conditions .
    Asperilin
  • HY-173599
    NUV-244

    		PNPLA3 Cancer
    NUV-244 is a PNPLA3 I148M degrader. NUV-244 reduces PNPLA3 I148M levels on lipid droplets via BFAR-mediated ubiquitin-proteasome degradation .
    NUV-244
  • HY-N13248
    Mulberry Leaf Extract

    		Glycosidase Metabolic Disease
    Mulberry Leaf Extract is a mulberry leaf extract, and its components include: 1-Deoxynojirimycin. Mulberry Leaf Extract can effectively alleviate the adverse effects of high-fat diet on blood lipids and renal function, regulate lipid metabolism abnormalities, and significantly inhibit the accumulation of glycosylated substances in glomeruli. Mulberry Leaf Extract can regulate the key signaling pathways of diabetic nephropathy, but does not directly affect blood glucose levels. .
    Mulberry Leaf Extract
  • HY-148626
    CVI-LM001

    		PCSK9 Metabolic Disease
    CVI-LM001 is an inhibitor PCSK 9. CVI-LM001 inhibits the interaction of PCSK9 with low-density lipoprotein receptor (LDLR), regulates the level of low-density lipoprotein cholesterol (LDL-C) in the blood, and exhibits lipid-lowering efficacy .
    CVI-LM001
  • HY-176212
    Ferroptosis-IN-20

    		Ferroptosis VDAC Reactive Oxygen Species (ROS) Inflammation/Immunology
    Ferroptosis-IN-20 (Compound 34a) is a Ferroptosis inhibitor (EC50: 24.2 nM) targeting voltage-dependent anion channel (VDAC). Ferroptosis-IN-20 inhibits VDAC oligomerization and lipid peroxidation. Ferroptosis-IN-20 reduces content of ROS, attenuates TFR1-mediated iron uptake, inhibits Fe 2+ level and restores glutathione (GSH) level. Ferroptosis-IN-20 alleviates Folic acid (HY-16637)-induced acute kidney injury (AKI) .
    Ferroptosis-IN-20
  • HY-W709961
    5-OAHSA

    1-(3-Carboxypropyl)tetradecyl (9Z)-9-octadecenoate

    		 Endogenous Metabolite Metabolic Disease Inflammation/Immunology
    5-OAHSA (1-(3-Carboxypropyl)tetradecyl (9Z)-9-octadecenoate) is a endogenous lipid. 5-OAHSA reduces the level of blood glucose, improves the glucose tolerance, and stimulates the the secretion of GLP-1 and insulin. 5-OAHSA exhibits potential in regulating metabolic and inflammatory responses .
    5-OAHSA
  • HY-B0757
    Vitamin E nicotinate

    		Reactive Oxygen Species (ROS) Cardiovascular Disease Inflammation/Immunology
    Vitamin E nicotinate is the derivative of Vitamin E. Vitamin E nicotinate exhibits antioxidant activity and prevents lipid peroxidation. Vitamin E nicotinate upregulates levels of CD4+ T cells and IL-2, exhibits immunomodulatory activity. Vitamin E nicotinate exhibits antiplatelet and antihypertensive activities, that can be used in atherosclerosis and thrombosis ressearch .
    Vitamin E nicotinate
  • HY-178389
    GPX4-IN-20

    		Molecular Glues Glutathione Peroxidase Ferroptosis Reactive Oxygen Species (ROS) Cancer
    GPX4-IN-20, a Arctigenin (HY-N0035) derived, is a GPX4& molecular gluedegrader. GPX4-IN-20 induces ferroptosis by increasing lipid ROS levels and suppressing GSH levels. GPX4-IN-20 reduces the protein expression and enzyme activity of GPX4 in a dose-dependent manner without affecting other ferroptosis-related proteins. GPX4-IN-20 induces ubiquitination-dependent proteasomal degradation of GPX4. GPX4-IN-20 also increases the level of malondialdehyde (MDA) in HCT-116 cells. GPX4-IN-20 can be used for the research of colorectal cancer .
    GPX4-IN-20
  • HY-108922
    Probucol disuccinate

    		Drug Derivative Metabolic Disease
    Probucol Disuccinate is a derivative of Probucol (HY-B0388), a lipid-regulating agent and can reduce LDL-cholesterol levels .
    Probucol disuccinate
  • HY-B2078
    Eprazinone

    		Neurokinin Receptor Inflammation/Immunology
    Eprazinone can enhance lung function and arterial oxygen levels and can be used in the study of chronic bronchitis. Higher doses of eprazinone increased phospholipid levels and decreased neutral lipid content in bronchoalveolar lavage (BAL) fluid, but had no effect on protein and cell levels in BAL. Eprazinone dose-dependently reduced short-circuit current (Isc), primarily by reducing chloride secretion at lower concentrations and affecting sodium and chloride transport at higher doses. Eprazinone may exert its anti-inflammatory effects by regulating BAL lipid composition and airway ion transport .
    Eprazinone

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: